BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24947923)

  • 21. Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model.
    Wu C; Jiang XL; Shen HW; Yu AM
    Biochem Pharmacol; 2009 Sep; 78(6):617-24. PubMed ID: 19445902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia.
    Nishizawa K; Yoda N; Morokado F; Komori H; Nakanishi T; Tamai I
    PLoS One; 2019; 14(4):e0214862. PubMed ID: 30951542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans.
    Lessard E; Yessine MA; Hamelin BA; Gauvin C; Labbé L; O'Hara G; LeBlanc J; Turgeon J
    J Clin Psychopharmacol; 2001 Apr; 21(2):175-84. PubMed ID: 11270914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of cimetidine, a model drug for inhibition of the organic cation transport (OCT2/MATE1) in the kidney, on the pharmacokinetics of glycopyrronium.
    Dumitras S; Sechaud R; Drollmann A; Pal P; Vaidyanathan S; Camenisch G; Kaiser G
    Int J Clin Pharmacol Ther; 2013 Oct; 51(10):771-9. PubMed ID: 24040847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.
    Czito BG; Deming DA; Jameson GS; Mulcahy MF; Vaghefi H; Dudley MW; Holen KD; DeLuca A; Mittapalli RK; Munasinghe W; He L; Zalcberg JR; Ngan SY; Komarnitsky P; Michael M
    Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):418-426. PubMed ID: 28497757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimizing polymorphic metabolism in drug discovery: evaluation of the utility of in vitro methods for predicting pharmacokinetic consequences associated with CYP2D6 metabolism.
    Gibbs JP; Hyland R; Youdim K
    Drug Metab Dispos; 2006 Sep; 34(9):1516-22. PubMed ID: 16763018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.
    Shen HW; Wu C; Jiang XL; Yu AM
    Biochem Pharmacol; 2010 Jul; 80(1):122-8. PubMed ID: 20206139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of CYP2D6 Poor Metabolizer Phenotype on Stereoselective Nebivolol Pharmacokinetics.
    Vieira CP; Neves DV; Coelho EB; Lanchote VL
    Drug Metab Lett; 2018; 12(1):68-70. PubMed ID: 29676238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis.
    Zhang L; Brown SJ; Shan Y; Lee AM; Allen JD; Eum S; de Leon J; Bishop JR
    Pharmacotherapy; 2020 Jul; 40(7):632-647. PubMed ID: 32519344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.
    Lee J; Moy S; Meijer J; Krauwinkel W; Sawamoto T; Kerbusch V; Kowalski D; Roy M; Marion A; Takusagawa S; van Gelderen M; Keirns J
    Clin Drug Investig; 2013 Jun; 33(6):429-40. PubMed ID: 23625188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6.
    Madeira M; Levine M; Chang TK; Mirfazaelian A; Bellward GD
    Drug Metab Dispos; 2004 Apr; 32(4):460-7. PubMed ID: 16680870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
    Zhou SF
    Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine.
    Nguyen HQ; Callegari E; Obach RS
    Drug Metab Dispos; 2016 Oct; 44(10):1569-78. PubMed ID: 27440861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interaction of Cisplatin with the human organic cation transporter 2.
    Filipski KK; Loos WJ; Verweij J; Sparreboom A
    Clin Cancer Res; 2008 Jun; 14(12):3875-80. PubMed ID: 18559608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a Physiologically Based Pharmacokinetic Model for Prediction of Pramipexole Pharmacokinetics in Parkinson's Disease Patients With Renal Impairment.
    You X; Wu W; Xu J; Jiao Z; Ke M; Huang P; Lin C
    J Clin Pharmacol; 2020 Aug; 60(8):999-1010. PubMed ID: 32090332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach.
    Kneller LA; Hempel G
    Pharm Res; 2020 May; 37(6):110. PubMed ID: 32476097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
    Higgins JW; Bedwell DW; Zamek-Gliszczynski MJ
    Drug Metab Dispos; 2012 Jun; 40(6):1170-7. PubMed ID: 22407892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elucidation of
    Miyake T; Mizuno T; Takehara I; Mochizuki T; Kimura M; Matsuki S; Irie S; Watanabe N; Kato Y; Ieiri I; Maeda K; Ando O; Kusuhara H
    Drug Metab Dispos; 2019 Nov; 47(11):1270-1280. PubMed ID: 31511257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney.
    Ito S; Kusuhara H; Yokochi M; Toyoshima J; Inoue K; Yuasa H; Sugiyama Y
    J Pharmacol Exp Ther; 2012 Feb; 340(2):393-403. PubMed ID: 22072731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine.
    Müller F; König J; Hoier E; Mandery K; Fromm MF
    Biochem Pharmacol; 2013 Sep; 86(6):808-15. PubMed ID: 23876341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.